Expression and prognosis analysis of MRPL12 in lung adenocarcinoma

doi:10.3969/j.issn.1674-8115.2021.08.006

Abstract

Abstract: Objective

·To analyze the difference of expression of mitochondrial ribosomal protein L12 (MRPL12) in lung adenocarcinoma (LUAD) and normal tissues and its influence on the prognosis of patients, and predict its biological function.

Methods

·The expressions of MRPL12 in different cancer tissues were analyzed by The Cancer Genome Atlas (TCGA) using the tumor-infiltrating immune cell analysis database TIMER and GEPIA (gene expression profiling and interactive analyses) server. The expressions of MRPL12 in different types of cancer were analyzed by Sangerbox bioinformatics platform. Cox regression and Kaplan-Meier survival analysis were used and the hazard ratios (HR), the 95% confidence intervals (CI) and the Log-rank P values were evaluated. The LinkedOmics database was used to identify the genes associated with MRPL12 expression. The DAVID database was used for the enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The transcription levels of MRPL12 in cells were verified by quantitative PCR (qPCR).

Results

·MRPL12 was highly expressed in many cancer types. But only the LUAD patients with high MRPL12 expression had lower overall survival (OS) and disease-specific survival (DSS). The expression of MRPL12 protein increased with tumor stage and individual tumor grade. The genes negatively related to MRPL12 were enriched into several cancer-related pathways in LUAD gene expression data set, including pathways in cancer (P=0.000), proteoglycans in cancer (P=0.000) and non-small cell lung cancer (P=0.000). The mRNA expression levels of MRPL12 in the LUAD cells (H1395, H1975 and HCC827) were higher than that in the normal cell (Beas-2B), and the difference was statistically significant (P<0.05).

Conclusion

·The LUAD patients with high expression of MRPL12 may have poor prognosis, and thus MRPL12 can be a potential biomarker and potential therapeutic target for LUAD.

Key words: lung adenocarcinoma (LUAD), mitochondrial ribosomal protein L12 (MRPL12), survival analysis, prognosis, biomarker, therapeutic target

CLC Number:

R734.2

Lei XIONG, Qian YI, Ming-fang XU, Jian CHEN. Expression and prognosis analysis of MRPL12 in lung adenocarcinoma[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1033-1040.

Figures/Tables 6

Fig1 Expression levels of MRPL12 in different cancers

Fig 2 Relationship between MRPL12 expression and OS and DSS in LUAD patients

Fig 3 Relationship between protein expression of MRPL12 and clinicopathological parameters in LUAD tissues

Fig 4 MRPL12 co-expression genes in LUAD tissues based on LinkedOmics database

Fig 5 KEGG enrichment analysis of MRPL12-negatively-correlated genes in LUAD tissues

Fig 6 The mRNA expression levels of MRPL12 in cell lines

TrendMD

References 30

1	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2	Wu C, Li M, Meng H, et al. Analysis of status and countermeasures of cancer incidence and mortality in China[J]. Sci China Life Sci, 2019, 62(5): 640-647.
3	Villalobos P, Wistuba II. Lung cancer biomarkers[J]. Hematol Oncol Clin North Am, 2017, 31(1): 13-29.
4	Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer[J]. Expert Opin Investig Drugs, 2014, 23(5): 675-692.
5	Porporato PE, Filigheddu N, Pedro JMB, et al. Mitochondrial metabolism and cancer[J]. Cell Res, 2018, 28(3): 265-280.
6	Kim HJ, Maiti P, Barrientos A. Mitochondrial ribosomes in cancer[J]. Semin Cancer Biol, 2017, 47: 67-81.
7	Senft D, Ronai ZA. Regulators of mitochondrial dynamics in cancer[J]. Curr Opin Cell Biol, 2016, 39: 43-52.
8	Marty L, Taviaux S, Fort P. Expression and human chromosomal localization to 17q25 of the growth-regulated gene encoding the mitochondrial ribosomal protein MRPL12[J]. Genomics, 1997, 41(3): 453-457.
9	Wang ZB, Cotney J, Shadel GS. Human mitochondrial ribosomal protein MRPL12 interacts directly with mitochondrial RNA polymerase to modulate mitochondrial gene expression[J]. J Biol Chem, 2007, 282(17): 12610-12618.
10	Serre V, Rozanska A, Beinat M, et al. Mutations in mitochondrial ribosomal protein MRPL12 leads to growth retardation, neurological deterioration and mitochondrial translation deficiency[J]. Biochim Biophys Acta, 2013, 1832(8): 1304-1312.
11	Sy SM, Wong N, Mok TS, et al. Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity[J]. Lung Cancer, 2003, 41(1): 91-99.
12	Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(w1): W509-W514.
13	Tang ZF, Li CW, Kang BX, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
14	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658.
15	Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(d1): D956-D963.
16	Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1): 44-57.
17	Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol, 2011, 12(2): 175-180.
18	Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments[J]. Arch Pathol Lab Med, 2013, 137(9): 1191-1198.
19	邓垒, 张文珏, 周宗玫, 等. 327例广泛期小细胞肺癌综合治疗的疗效分析[J]. 国际放射医学核医学杂志, 2018, 42(1): 1-8.
20	Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
21	Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929.
22	Surovtseva YV, Shutt TE, Cotney J, et al. Mitochondrial ribosomal protein L12 selectively associates with human mitochondrial RNA polymerase to activate transcription[J]. PNAS, 2011, 108(44): 17921-17926.
23	Amunts A, Brown A, Toots J, et al. Ribosome. The structure of the human mitochondrial ribosome[J]. Science, 2015, 348(6230): 95-98.
24	Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease[J]. Oncotarget, 2015, 6(7): 4569-4584.
25	Marty L, Fort P. A delayed-early response nuclear gene encoding MRPL12, the mitochondrial homologue to the bacterial translational regulator L7/L12 protein[J]. J Biol Chem, 1996, 271(19): 11468-11476.
26	Nouws J, Goswami AV, Bestwick M, et al. Mitochondrial ribosomal protein L12 is required for POLRMT stability and exists as two forms generated by alternative proteolysis during import[J]. J Biol Chem, 2016, 291(2): 989-997.
27	Zhang QL, Liang Z, Gao YX, et al. Differentially expressed mitochondrial genes in breast cancer cells: potential new targets for anti-cancer therapies[J]. Gene, 2017, 596: 45-52.
28	Vatapalli R, Sagar V, Rodriguez Y, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer[J]. Nat Commun, 2020, 11(1): 4153.
29	Ge Z, Guo X, Li JY, et al. Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia[J]. Oncotarget, 2015, 6(39): 42300-42311.
30	Müller J, Eilers M. Ubiquitination of Myc: proteasomal degradation and beyond[J]. Ernst Schering Found Symp Proc, 2008(1): 99-113.

[1]	Sheng CHEN, Zhi-long YAN, Ye-ming WU, Min XU, Song GU, Jing MA. Expression and clinical significance of HIF-1α/SHH signaling pathway in neuroblastoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1056-1061.
[2]	Xu-xin-yi LING, Yao ZHANG, Hua ZHONG. Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1114-1119.
[3]	Sheng CHENG, Yi ZHAO, Yong-chen WANG, Ping HUANG. Meta-analysis of the effect of BRAF gene mutation on the prognosis of colorectal cancer patients with liver metastases after hepatectomy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 786-792.
[4]	Xu-guang CHEN, Sheng-yi SHI, Lan HU, Yu CHEN, Yi-ming LU, Jing YE. Evaluative value of plasma fibrin degradation product in early prognosis of patients with hemorrhagic stroke [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 612-616.
[5]	Ru-juan BAO, Hui-fang CHEN, Yu DONG, You-qiong YE, Bing SU. Construction of prognostic risk score model of colorectal cancer gene signature based on transcriptome dysregulation [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 285-296.
[6]	Ren-yan WU, Xiao-lin GUO, Deng-li HONG, Lei CHEN. Identification of potential therapeutic target genes in pediatric acute leukemia of ambiguous lineage based on bioinformatics analysis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 320-327.
[7]	Yan-ru MA, Lin-hua JI, Tian-ying TONG, Yu-qing YAN, Chao-qin SHEN, Xin-yu ZHANG, Ying-ying CAO, Jie HONG, Hao-yan CHEN. Establishment and validation of prognostic prediction model of colorectal cancer based on single-cell RNA sequencing [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 159-165.
[8]	Pei-kun HU, Jie HE, Lian-ming WU, Heng GE, Jian-rong XU, Jun PU. Effect of microvascular obstruction on left ventricle function and prognosis in patients with ST-segment elevation myocardial infarction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 173-179.
[9]	Zhong-mao FU, Zai LUO, Ze-yin RONG, Jian-ming ZHANG, Teng-fei LI, Zhi-long YU, Chen HUANG. Study on the function and prognosis of circular RNA in colorectal cancer tissues based on high-throughput sequencing [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 187-195.
[10]	CHEN Si, LIU Chun-liang, ZHAO Qian, SUN Hai-peng, LIU Yun-xia. Identification of hub genes and key pathways in breast cancersurvival-based bioinformatics analysis [J]. , 2020, 40(3): 294-.
[11]	TANG Dong-juan, XUE Xiao-mei, HE Bin. Early diagnosis and prognostic evaluation value of miR-133a in patients with acute myocardial infarction [J]. , 2020, 40(3): 339-.
[12]	YE Xin, ZHOU Xiao-yun, YANG Li, WANG Jie, HE Qi. Analysis of clinicopathological features and prognosis of young patients with breast cancer in different age groups [J]. , 2020, 40(3): 351-.
[13]	LIU Jin-yan, ZHAO Jun-tao, WANG Heng-ru, HUANG Jia-yi, WANG Yu-ting, XIANG Ming-jie. Effect of cytoskeleton-associated protein 4 on tumor diagnosis and prognosis [J]. , 2020, 40(2): 255-.
[14]	ZHANG Wei-ran1, 2, LIN Xue-feng3, LI Xin2, ZHANG Hao2, WANG Meng2, SUN Wei2, HAN Xing-peng2, SUN Da-qiang1, 4. Transcriptional identification of potential biomarkers of lung adenocarcinoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1598-1606.
[15]	HE Chun-ming, YIN Hang, TANG Jian, DING Yi-zong, FU Yu-jie, ZHAO Xiao-jing. Establishment and internal validation of a prognostic model for elderly patients after lung cancer surgery based on SEER [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1554-1561.